Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 2/20 | 0.40 |
| ▸ | FNTA | P49354 | 4/20 | 0.40 |
| ▸ | FNTB | P49356 | 4/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP4 | P49662 | 1/20 | 0.39 |
| ▸ | CASP5 | P51878 | 1/20 | 0.39 |
| ▸ | CASP9 | P55211 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.39 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640025 | 0.91 | BACE1 (0.48) | BACE1BACE2CTSD | |
| SCHEMBL29683498 | 0.91 | BACE1 (0.40) | BACE1BACE2CTSDFNTAFNTB | |
| SCHEMBL30441425 | 0.89 | SLC15A2 (0.43) | BACE1BACE2CTSDFNTAFNTB | |
| SCHEMBL30020949 | 0.88 | BACE1 (0.49) | BACE1BACE2CTSDCASP3 | |
| SCHEMBL30567747 | 0.88 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL29421173 | 0.88 | BACE1 (0.38) | BACE1CTSDFNTAFNTBCASP3 | |
| SCHEMBL31514368 | 0.87 | BACE1 (0.49) | BACE1BACE2CTSD | |
| SCHEMBL31187019 | 0.87 | BACE1 (0.42) | BACE1BACE2CTSDCASP1CASP3 | |
| SCHEMBL21529464 | 0.87 | BACE1 (0.42) | BACE1BACE2CTSDCASP1CASP3 | |
| SCHEMBL30142012 | 0.87 | PTPN1 (0.39) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | VIP, ARGLU1, PELP1 | BACE1 1112/4885BACE2 2417/4885CTSD 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.